Assessment of predictive indicators of acute gastrointestinal toxicity using in vivo transmission images.

For pelvic and abdominal treatments, excess dose to the bowel can result in acute toxicities. Current estimates of bowel toxicity are based on pre-treatment dose-volume histogram data. However, the actual dose the bowel receives depends on interfraction variations, such as patient anatomy changes. We propose a method to model bowel toxicities, incorporating in vivo patient information using transit electronic portal imaging device (EPID) images. For 63 patients treated to the lower thorax, abdomen, or pelvis on the Varian Halcyon, weekly chart review was performed to obtain incidences of grade 2 or higher toxicity, RTOG scale. Twenty patients presented with acute gastrointestinal (GI) toxicity. All patients were treated with conventional fractionation. For each treatment plan, the absolute volume dose-volume histogram of the bowel was exported and analyzed. Additionally, for each fraction of treatment, in vivo EPID images were collected and used to estimate the change in radiation transmission during the course of treatment. A logistic model was used to test correlations between acute GI toxicity and bowel dosimetric parameters as well as metrics obtained from in vivo image measurements. After performing the fit to the in vivo EPID data, the bootstrap resampling method was used to create confidence intervals. In vivo EPID image metrics from an additional 42 patients treated to the lower thorax, abdomen, or pelvis were used to validate the logistic model fit. The incidence of toxicity versus the volume of 40 Gy to the bowel space was fitted with a logistic function, which was superior to an average model (p < 0.0001) and agrees with previously published models. For the initial in vivo EPID data, the incidence of toxicity versus the sum of in vivo transmission measurements showed marginal significance after 15 fractions (p = 0.10) of treatment and a significance of p = 0.038 is seen at the 20th fraction, when compared to an average model. For the validation data set, the logistic model of the in vivo transmission measurement after 20 fractions was superior to the average model (p = 0.043), with the model falling within the 68% confidence interval of the fit of the initial data set. Dose-volume constraints to reduce the incidence of acute GI toxicity have been validated. The presented novel EPID transmission-based metric can be used to identify GI toxicity as patients progress through treatment.

Informations de copyright

© 2021 American Association of Physicists in Medicine.